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 Implication for health policy/practice/research/medical education:
Management of subclinical hyperthyroidism is not always straightforward. Good practice requires a systematic study and careful 
evaluation. The need of treatment of this frequent disorder must be individualized.
1. Background
1.1. What is Subclinical Hyperthyroidism?
Subclinical hyperthyroidism is characterized by circulat-
ing thyrotropin (thyroid-stimulating hormone; TSH) levels 
below the reference range and normal serum thyroid hor-
mone levels (1). The diagnosis is primarily biochemical and 
depends on the definition of “normal” TSH levels. In 2002, a 
The ideal approach for adequate management of subclinical hyperthyroidism (low levels 
of thyroid-stimulating hormone [TSH] and normal thyroid hormone level) is a matter of 
intense debate among endocrinologists. The prevalence of low serum TSH levels ranges 
between 0.5% in children and 15% in the elderly population. Mild subclinical hyperthyroid-
ism is more common than severe subclinical hyperthyroidism. Transient suppression of 
TSH secretion may occur because of several reasons; thus, corroboration of results from 
different assessments is essential in such cases. During differential diagnosis of hyperthy-
roidism, pituitary or hypothalamic disease, euthyroid sick syndrome, and drug-mediated 
suppression of TSH must be ruled out. A low plasma TSH value is also typically seen in 
the first trimester of gestation. Factitial or iatrogenic TSH inhibition caused by excessive 
intake of levothyroxine should be excluded by checking the patient’s medication history. 
If these nonthyroidal causes are ruled out during differential diagnosis, either transient 
or long-term endogenous thyroid hormone excess, usually caused by Graves’ disease or 
nodular goiter, should be considered as the cause of low circulating TSH levels.
We recommend the following 6-step process for the assessment and treatment of this 
common hormonal disorder: 1) confirmation, 2) evaluation of severity, 3) investiga-
tion of the cause, 4) assessment of potential complications, 5) evaluation of the neces-
sity of treatment, and 6) if necessary, selection of the most appropriate treatment.
In conclusion, management of subclinical hyperthyroidism merits careful monitoring 
through regular assessment of thyroid function. Treatment is mandatory in older patients 
(> 65 years) or in presence of comorbidities (such as osteoporosis and atrial fibrillation).
panel of experts established the reference range for serum 
THS levels between 0.45 and 4.5 µU/mL (National Health 
and Nutrition Examination Survey [NHANES] III) (2) Howev-
er, many specialists have proposed a reconsideration of this 
reference range in the light of data suggesting that, under 
certain circumstances, serum THS levels less than 4.5 µU/mL 
could mask thyroid dysfunction (3-9). Therefore, various as-
pects relevant to clinical practice should be considered in 
this regard. First, the traditional “one size fits all” policy can-
not be applied to fix the reference range of circulating thy-
roid hormone levels. While interpreting serum TSH levels, 
physiological variations as well as presence of occult thy-
roid disease should be considered. Several anthropomet-
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ric variables, including age, gender, race, and body mass 
index (BMI), have a noticeable influence over circulating 
TSH levels (8-10). In addition, other factors such as concur-
rent medication, coexisting pregnancy, or concomitant dis-
eases should be considered in order to correctly interpret 
TSH, thyroxin (T4), and triiodothyronine (T3) status (8). As 
mentioned earlier, the definitions of both subclinical and 
overt hyperthyroidism (abnormal TSH with high thyroid 
hormone levels) are primarily biochemical, because the 
signs and symptoms of hyperthyroidism are nonspecific 
and may be present in patients with subclinical disease and 
absent in those with overt disease, especially in the elderly 
population. Additionally, clinicians should consider 3 im-
portant facts while interpreting the results of thyroid func-
tion tests (11): 1) TSH secretion follows a circadian rhythm 
with higher values early in the morning and lowest value in 
the afternoon; 2) THS secretion is pulse-regulated; and 3) 
THS half-life is about 15 min.
1.2. How to Screen for Thyroid Disease?
 Although systematic screening for subclinical thyroid 
dysfunction is not recommended by the 2004 American 
experts’ task force, identification of cases in high-risk 
populations is highly advisable (12). However, serum TSH 
determination is universally regarded as the best test for 
the initial assessment of thyroid dysfunction (13). The 
plausible biochemical findings in patients with subclini-
cal thyroid disease range between mild and severe dys-
function. A classification system for subclinical hyperthy-
roidism has been proposed recently, which differentiates 
between low serum TSH levels (0.1–0.4 µU/mL; Grade I or 
mild) and suppressed TSH concentration (< 0.1 µU/mL; 
Grade II or severe) (14). Grade I subclinical hyperthyroid-
ism is 3 to 4 times more common than Grade II subclini-
cal hyperthyroidism. The risk of progression from Grade 
I to overt disease is very low. Conversely, about 2% to 5% 
of the cases of Grade II hyperthyroidism progress to 
clinical disease per year (14). In some cases, subclinical 
hyperthyroidism may present with a normal serum level 
of free T4 (FT4) while the serum T3 level remains above 
the reference range. This unusual laboratory finding has 
been called “T3-toxicosis” and may represent the earliest 
stages of disease, which is normally caused by an autono-
mously functioning thyroid nodule (1). All these catego-
ries are relevant in clinical practice.
1.3. What is the Origin of Subclinical Hyperthyroidism?
Thyrotoxicosis can be exogenous or endogenous. Hy-
perthyroidism caused by underlying pituitary or hypo-
thalamic disease should always be excluded during the 
differential diagnosis of subclinical hyperthyroidism 
(Sidebar). 
Exogenous subclinical thyrotoxicosis: This is the most 
common type of subclinical hyperthyroidism. Irrespec-
tive of the cause of hypothyroidism, thyroid blood tests 
in overtreated hypothyroid patients show results consis-
tent with those of subclinical hyperthyroidism. Similar 
findings are observed in many patients with a history of 
differentiated thyroid cancer, in which the therapeutic 
target is to achieve and maintain TSH suppression by ad-
ministering supraphysiological doses of levothyroxine 
(LT4). Thus, factitial or iatrogenic THS suppression due 
to excessive intake of LT4 should always be excluded by 
history-taking during the differential diagnosis of sub-
clinical hyperthyroidism. 
Endogenous hyperthyroidism: Subclinical overactive 
thyroid dysfunction similar to that in overt hyperthy-
roidism may be caused by Graves’ disease, toxic multi-
nodular goiter, toxic adenoma, and different types of 
thyroiditis (15). 
Miscellaneous conditions: TSH secretion may be tran-
siently suppressed because of other causes such as euthy-
roid sick syndrome or concomitant use of TSH-suppressing 
drugs, e.g., steroids, dobutamine, amiodarone, and dopa-
mine. These conditions are usually associated with low 
or low–normal serum T4 and T3 levels (16), and therefore, 
should be ruled out in the differential diagnosis of subclini-
cal hyperthyroidism. Moreover, low TSH levels are also nor-
mally seen in the first trimester of pregnancy (17).
2. Patients and Methods
After the diagnosis of subclinical hyperthyroidism, 
management of the condition involves the following 
6 steps: 1) confirmation, 2) assessment of severity, 3) 
determination of the cause, 4) assessment of potential 
complications, 5) evaluation of the necessity of treat-
ment, and 6) selection of the most convenient therapy, 
in patients who require treatment. A flowchart summa-
rizing this process is displayed in Figure 1. These steps 
should be followed for all patients, irrespective of their 
age, although elderly patients should receive thorough 
management.
Origin Condition
Endogenous
Persistent
Transient
Other
Toxic Adenoma
Toxic Multinodular Goiter
Graves’ disease
Pituitary disease (Central hypothyroidism) a
Subacute thyroiditis
Silent thyroiditis
Postpartum thyroiditis
Euthyroid Sick Syndrome
Initial post-therapy period after treatment for 
overt hyperthyroidism
Pregnancy (especially during the first trimester)
Exogenous
Iatrogenic Overtreatment with levothyroxine (most com-
mon cause)
Factitial thyrotoxicosis (surreptitious levothy-
roxine intake)
Drug-induced thyroiditis (amiodarone, α-IFN)
Iodide excess (radiographic contrasts) 
TSH-lowering medications (steroids, dopamine)
Sidebar . Causes of Subclinical Hyperthyroidism (or Low Serum TSH Level)
a Usually associated with low Thyroxin and low Triiodothyronine
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2.1. Confirmation of the Diagnosis of Subclinical Hyper-
thyroidism
A case showing low serum TSH concentration with 
normal levels of peripheral thyroid hormones in ab-
sence of symptoms requires further confirmation with 
a complete thyroid profile analysis, including assess-
ments of serum FT4 and T3 levels, after 1–3 months. If 
symptoms (such as cardiac arrhythmias) suggestive of 
hyperthyroidism are present, TSH measurement should 
be repeated after 2 weeks (18). Some reports indicate 
that approximately 50% of the cases of abnormal serum 
TSH levels resolve spontaneously, especially in Grade I 
(9-21). Spontaneous remission is more likely in subclini-
cal Graves’ disease than in toxic multinodular goiter; 
accordingly, subclinical hyperthyroidism due to auton-
omous nodule(s) is more likely to progress to overt hy-
perthyroidism than that related to Graves’ disease (22). 
Patients showing consistently low TSH levels in repeated 
measurements for over a 3–6-month period should be di-
agnosed as having a thyroid disorder (1).
2.2. Severity Assessment
Patients showing persistently very low serum TSH 
values (< 0.1 µU/mL; Grade II) should be treated for the 
underlying cause of subclinical hyperthyroidism. Treat-
ment is mandatory in patients aged over 65 years and in 
patients with associated comorbidities (such as heart dis-
ease or osteoporosis) or symptoms suggestive of hyper-
thyroidism (see section 5). A confirmed finding of mild 
to low serum TSH values (0.1–0.4 µU/mL; Grade I) indi-
cates that treatment may be not necessary (23). However, 
careful monitoring of this group of untreated patients 
is recommended. Periodic assessment should include 
measurement of TSH, FT4, and T3 levels every 6 months. 
In contrast, symptomatic, elderly patients (> 65 years), 
and patients with underlying cardiovascular diseases 
should always receive appropriate treatment. Addition-
ally, treatment is also recommended for patients who 
show a positive thyroid radionuclide scan with 1 or more 
focal areas of increased uptake (evidence of autonomy).
2.3. Determination of the Causes of Subclinical Hyper-
thyroidism
As mentioned earlier, TSH may be transiently sup-
pressed because of various reasons (Sidebar). Investiga-
tion and confirmation of the cause are important steps 
during follow up. The most common cause of endoge-
nous subclinical hyperthyroidism is release of excess thy-
roid hormone by the thyroid gland (1). In older persons, 
toxic multinodular goiter is probably the most common 
cause of subclinical hyperthyroidism (24). Nevertheless, 
patients should be inquired about any current medica-
tion that they may be using because some frequently 
Figure 1. Flowchart for Management of Subclinical Hyperthyroidism
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used drugs (such as steroids or exogenous T4) inhibit pi-
tuitary TSH secretion, especially in older patients. Serum 
TSH concentrations in treated hyperthyroid patients or 
in those recovering from the thyrotoxic phase of thy-
roiditis may remain low even several months after nor-
malization of circulating T4 and T3 levels. Transient low 
serum TSH levels are considered normal during the first 
trimester of pregnancy. True subclinical hyperthyroid-
ism may occur in pregnant women, but it is not typically 
associated with adverse outcomes during pregnancy 
and does not require therapy (25). Individuals with cen-
tral hypothyroidism generally have low serum TSH levels 
and normal (but usually low or low–normal) FT4 and T3 
levels. Some studies have reported the existence of an 
altered set point of the hypothalamic–pituitary–thyroid 
axis in some healthy elderly people (26, 27). Elderly peo-
ple may have low serum TSH levels and low–normal se-
rum levels of FT4 and T3, without evidence of thyroid or 
pituitary disease (28, 29).
2.4. Assessment of Potential Complications
Clinical manifestations of both overt and mild (or sub-
clinical) thyrotoxicosis are similar, but differ in magni-
tude. Potential complications of untreated subclinical 
hyperthyroidism are numerous and include weight loss, 
osteoporosis, atrial fibrillation, embolic events, and al-
tered cognition. The most profound consequences of 
subclinical overactive thyroid dysfunction are observed 
on the cardiovascular system (30) and the skeleton (16). 
The following potential complications are of utmost im-
portance in elderly patients. 
Bone and mineral metabolism: Thyroid hormones di-
rectly stimulate bone resorption. Changes induced by 
the thyroid hormones are mainly observed in the corti-
cal bone (wrist), to a significantly low extent in the tra-
becular bone (spine), and to an intermediate extent in 
the mixed cortical–trabecular bone (hip). Whether sub-
clinical hyperthyroidism increases the fracture rate in 
the normal population is a matter of intense debate (31). 
However, postmenopausal women with subclinical hy-
perthyroidism may have high fracture rates even though 
they show only mildly suppressed serum TSH levels (31, 
32). Therefore, to rule out osteoporosis, it is advisable to 
include a bone mineral densitometric study in the as-
sessment of these patients.
Cardiovascular effects: Subclinical hyperthyroidism 
has several negative effects on cardiac function. These ef-
fects are similar to, but milder and less frequent than, 
those of overt hyperthyroidism. In a recent population-
based study in Scotland, endogenous subclinical hy-
perthyroidism was associated with an increased risk of 
nonfatal cardiovascular disease (33). Additional related 
complications included tachycardia, atrial fibrillation, 
increased left ventricular mass index, increased cardiac 
contractility, impaired endothelial function, reduced 
exercise tolerance, reduced heart rate variability, and hy-
percoagulability (34, 35). The presence of cardiovascular 
complications is probably dependent on the degree of 
TSH suppression, the underlying cause of hyperthyroid-
ism, and the individual’s sensitivity to excess thyroid 
hormone. Small-scale uncontrolled studies have shown 
an improvement in cardiac parameters of patients after 
restoration of the euthyroid state (36, 37) or after treat-
ment with beta-adrenergic blocking drugs (38). Atrial 
fibrillation is a well-recognized complication of hyper-
thyroidism that commonly leads to embolic events. The 
frequency of atrial fibrillation is high in patients with 
subclinical hyperthyroidism. A prospective cohort study 
in approximately 2,000 adults (age > 60 years), with a 
follow-up period of 10 years, showed that low serum TSH 
level is a risk factor for atrial fibrillation (39). This study 
analyzed the relationship between serum TSH levels and 
the incidence of atrial fibrillation. Cumulative incidence 
rates of atrial fibrillation in subjects with serum TSH val-
ues lower than 0.1 µU/mL (Grade II subclinical hyperthy-
roidism), between 0.1 and 0.4 µU/mL (Grade I subclinical 
hyperthyroidism), and within the normal range were 
28%, 16%, and 11%, respectively. Analogous results were pub-
lished in another prospective cohort study that showed 
a relationship between subclinical hyperthyroidism and 
development of atrial fibrillation, although the data did 
not support the hypothesis that unrecognized subclini-
cal hyperthyroidism is related to cardiac disorders (40). 
Cardiovascular mortality as a complication of subclini-
cal hyperthyroidism is a matter that requires detailed 
investigation. All-cause and cardiovascular mortalities 
were assessed in a 10-year prospective study in a popu-
lation with low serum TSH level (41). The investigators 
found higher mortality rates at 1, 2, and 5 years of follow 
up, but not after 10 years. A recent meta-analysis of 5 pop-
ulation-based studies on subclinical thyroid dysfunction 
showed that the risk of cardiovascular mortality was not 
significant in the population with low serum TSH level 
(42). In contrast, another meta-analysis with a similar 
design showed that subclinical thyroid disease is asso-
ciated with an increased risk of all-cause mortality (43). 
Overall, the increased risk of mortality from subclinical 
hyperthyroidism appears to be low, but it could increase 
with age and degree of TSH suppression (43).
Dementia and depression: Although the data are con-
flicting, some authors have suggested that subclinical 
hyperthyroidism may be associated with dementia (33, 
44). In contrast, a cross-sectional study in 295 English 
patients diagnosed with subclinical thyroid dysfunction 
did not show any association between subclinical hyper-
thyroidism and depression, anxiety, or cognitive func-
tion (45).
2.5. Need for Treatment
In endocrinology, the necessity of treatment for pa-
tients with subclincal hyperthyroidism is an open ques-
tion (31, 46-50). The criteria for treatment of this disor-
der are controversial, and individualized judgment is 
mandatory in order to evaluate the grade and clinical 
consequences of the disorder in a given patient. Since 
prospective studies show that isolated low serum TSH 
levels spontaneously return to normal in nearly 50% of 
patients, caution and regular monitoring are the recom-
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mended initial approaches (31, 46). Additionally, only 5% 
of individuals with subclinical disease develop overt dys-
function yearly.
The 2004 American guidelines classified subclinical hy-
perthyroid patients according to the origin (endogenous 
or exogenous) and severity of the disorder. According to 
these guidelines, the treatment depends on the above-
mentioned criteria and should be decided after consid-
ering the risks and benefits in each case (31).
In any event, therapy strategies vary depending on 3 
key factors (47, 49, 50): 1) cause, 2) severity, and 3) as-
sociated morbidity.
1. Cause: Etiological diagnosis must be performed before 
the initiation of treatment.
Exogenous subclinical hyperthyroidism in patients 
receiving LT4 treatment only requires dose adjustment 
(31). However, it is necessary to consider that certain pa-
tients with a medical history of thyroid carcinoma need 
chronic TSH suppressive therapy in order to maintain 
undetectable circulating TSH levels.
Subclinical hyperthyroidism in patients with Graves’ 
disease should be medically treated, although experi-
mental data supporting this approach are limited (31). 
However, a number of patients with mild Graves’ disease 
develop spontaneous remission without therapy. There-
fore, periodic monitoring of thyroid function every 3 
months, without initiation of therapy, is a reasonable 
approach in young patients with mild subclinical hy-
perthyroidism caused by Graves’ disease (1). In contrast, 
subclinical hyperthyroidism caused by nodular hyper-
thyroidism usually requires ablative treatment because 
spontaneous normalization of thyroid function in this 
condition seldom occurs. Thus, surgery or administra-
tion of radioactive iodine is the treatment of choice in 
such cases.
The thyrotoxic phase of thyroiditis is transitory, with a 
middle-time (2 to 3 months) spontaneous remission, and 
usually needs no treatment or symptomatic treatment at 
the most (51).
2. Severity: In general, patients with Grade I subclinical 
hyperthyroidism may not be offered treatment. How-
ever, treatment of Grade I subclinical hyperthyroidism 
is warranted in elderly patients (> 65 years), in patients 
with cardiovascular disease, osteoporosis, and symp-
toms of hyperthyroidism, and postmenopausal women 
(especially those who have not been treated with estro-
gens or bisphosphonates) (1). Nevertheless, data regard-
ing the potential benefits of treatment in these patients 
are inconclusive. Restoration of serum TSH levels con-
tributes to bone mass preservation (52-54); however, nor-
malization of bone turnover rates may require several 
months (47, 49, 50). A recent meta-analysis suggested a 
progressive increase in mortality rates of people aged 
over 60 years with subclinical thyroid dysfunction (43). 
However, the 2004 American experts’ task force recom-
mends against routine treatment of patients with Grade 
I subclinical hyperthyroidism because the treatment nei-
ther benefits heart function nor improves arrhythmia in 
these patients (31). After careful consideration, the 2005 
Joint Statement from the American Association of Clini-
cal Endocrinologists concluded in favor of monitoring 
this group of patients (46). On the other hand, treatment 
should be strongly considered in high-risk individuals 
with persistent endogenous Grade II (TSH level < 0.1 µU/
mL) subclinical hyperthyroidism (14).
Notwithstanding the recent 2011 Guidelines, there are 
still insufficient data to recommend for or against treat-
ment of subclinical hyperthyroidism in young people 
with subclinical hyperthyroidism. A study on middle-
aged patients showed an improvement in hyperthyroid-
ism symptoms after treatment (36). However, in spite of 
the fact that the study did not include young people, the 
recent American Guidelines recommend treating all pa-
tients younger than 65 years with persistent and symp-
tomatic Grade II subclinical hyperthyroidism (1).
3. Associated morbidity. As has been repeatedly in-
dicated, the potential harmful effects associated with 
subclinical hyperthyroidism are the major reasons for 
starting specific treatment, as was recommended by the 
European Guidelines (48). These side effects are more 
evident in the elderly people and in patients with associ-
ated risk factors (48). Therefore, it is important to evalu-
ate whether the following specific clinical situations are 
present at diagnosis: 1) hyperactive thyroid dysfunction 
of nodular origin; 2) goiter; 3) symptoms of thyrotoxi-
cosis (generally nonspecific, such as fatigue, diarrhea, or 
palpitations); 4) cardiovascular disease (such as atrial 
fibrillation, angina, or heart failure); 5) bone or neuro-
muscular conditions; 6) gonadal dysfunction (oligo-
menorrhea, amenorrhea, or infertility); 7) old age (≥ 65 
years); 8) circulating T3 levels in the upper limit of the 
normal range; and 9) very low serum TSH levels (< 0.01 
µU/mL or severe Grade II).
2.6. Election of Treatment
The armamentarium for treatment of thyroid dysfunc-
tion is similar for overt and subclinical disease: medical 
therapy (antithyroid drugs and beta-adrenergic block-
ers), radioiodine administration, or surgery. The ratio-
nale and aim of subclinical hyperthyroidism therapy is 
to restore the euthyroid state and avoid potential side 
effects (36). 
Medical therapy: Antithyroid drug therapy (carbima-
zole or its metabolite methimazole) at low doses (5–10 
mg/day) is the treatment of choice in patients with 
Graves’ disease. Treatment should be continued, under 
adequate monitoring, for at least 6 months. Long-term 
treatment (over 12 to 18 months) is a sensible initial al-
ternative to radioiodine therapy, because the remission 
index is high in patients with mild disease, especially in 
young people (55). Carbimazole-related adverse effects 
are usually not severe and can normally be managed 
by changing the dose of the drug, although exceptional 
severe events (such as agranulocytosis) have been de-
scribed. Propylthiouracil could be an alternative option 
to carbimazole, but recent studies have warned practi-
tioners about the use of this drug (56). Propylthiouracil 
should never be used in children (57) or in adults, except 
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during early pregnancy when propylthiouracil may help 
avoid potential fetal malformations. In addition to caus-
ing liver disease, propylthiouracil is also associated with 
a greater risk of developing vasculitis and glomerulone-
phritis (58). Ablative treatment (surgery or radioiodine 
administration): Ablative therapy is generally safe and 
has no associated complications; however, ablation in 
asymptomatic patients is not advised. The presence of 
Graves’ orbitopathy normally precludes the administra-
tion of radioiodine. Ablation is the only definitive thera-
py for nodular hyperthyroidism (48). Surgical treatment 
is the recommended approach in young individuals with 
a single hyperfunctioning nodule (toxic adenoma) and 
in patients with toxic multinodular goiter (especially 
those showing compressive symptoms) or possible ma-
lignancy (1). Administration of radioactive iodine is ap-
propriate for most patients, especially those with toxic 
multinodular goiter or over 60 years of age (1) and is 
the best treatment option in patients with concomi-
tant heart disease. Either surgery or radioactive iodine 
administration may be recommended for patients with 
Graves’ disease if medical therapy fails.
Symptomatic treatment: Treatment with beta-blockers 
is recommended especially in the presence of adrenergic 
symptoms. Beta-blockers improve hyperthyroid symp-
toms and control cardiovascular morbidity, especially 
that caused by atrial fibrillation (38).
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